Pharmacorp Rx Inc.

As of June 30, 2026, Pharmacorp Rx Inc. carries a market capitalization of 87.04M, placing it among publicly traded companies globally. Its enterprise value stands at 67.85M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Pharmacorp Rx Inc.'s next confirmed earnings release is scheduled for November 26, 2026.

As of June 30, 2026, Pharmacorp Rx Inc. has 174.08M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.92, and the price-to-book ratio stands at 1.65.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.48 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 67.85M versus a market cap of 87.04M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Pharmacorp Rx Inc. maintains a current ratio of 7.36, meaning it holds 7.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.33, indicating elevated leverage, while an interest coverage ratio of -0.99 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Pharmacorp Rx Inc. posted a negative return on equity (ROE) of -2.75, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -2.29, reflecting losses generated across the asset base. The company generates approximately 5.48M in revenue per employee across its workforce of 5.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.88 indicates how many times Pharmacorp Rx Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Pharmacorp Rx Inc. recorded 279,332.00 in income tax expense. The company reported a pretax loss of -763,155.00 and -1.14M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Pharmacorp Rx Inc.'s stock has declined approximately 16.67% over the past 52 weeks. The 50-day moving average sits at 0.44, while the 200-day moving average is 0.46.

Over the twelve months ended June 30, 2026, Pharmacorp Rx Inc. generated 27.41M in revenue and converted that into -1.14M in net income, yielding earnings per share of -0.01. EBITDA reached -172,245.00, while operating income came in at -1.31M.

As of June 30, 2026, Pharmacorp Rx Inc. holds 24.01M in cash and equivalents against 4.43M in total debt, resulting in a net debt position of -20.57M. Total book value stands at 52.77M, with working capital of 24.95M providing operational flexibility.

Pharmacorp Rx Inc. produced 229,546.00 in operating cash flow over the twelve months ended June 30, 2026. After subtracting -186,598.00 in capital expenditures, free cash flow totaled 42,948.00 - equivalent to 0.00 per share.

Over the twelve months ended June 30, 2026, Pharmacorp Rx Inc. posted a gross margin of 39.53, reflecting its pricing power and cost economics. The operating margin of -4.77 and net profit margin of -4.16 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 0.05, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -29.03, meaning Pharmacorp Rx Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Pharmacorp Rx Inc. has an Altman Z-Score of 6.12, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.